Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral relugolix works to a T against advanced prostate cancer

Key clinical point: Relugolix, an oral gonadotropin-releasing hormone antagonist, was effective at suppressing testosterone levels over 48 weeks.

Major finding: At 48 weeks, 96.7% of men on relugolix and 88.8% on leuprolide had sustained testosterone suppression (P < .001).

Study details: Phase 3 trial of 930 men with advanced prostate cancer.

Disclosures: The study was supported by Myovant. Dr. Shore disclosed relationships with Myovant and other companies.

Citation:

Shore ND et al. ASCO 2020, Abstract 5602.